Diabetes Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Others), By Diabetes Type (Type 1, Type 2, Gestational), By Route of Administration (Oral, Subcutaneous, Intravenous), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, Others), By Region and Competition, 2020-2030F

Market Overview

Global Diabetes Drugs Market was valued at USD 89.45 Billion in 2024 and is expected to reach USD 137.17 Billion in the forecast period with a CAGR of 7.36% through 2030. The Global Diabetes Drugs Market is witnessing significant growth due to the rising prevalence of diabetes worldwide, especially Type 2 diabetes, which is closely linked to the growing adoption of unhealthy lifestyles, sedentary habits, and poor dietary choices. An aging population, which is more susceptible to chronic conditions like diabetes, also contributes to the increasing demand for diabetes medications. The rising awareness about the disease and its management options is leading to a greater number of patients seeking medical advice and treatment. This growing patient population, combined with advancements in diabetes drug development, is driving the market forward.

Innovations in drug formulations, such as the development of oral and injectable treatments with improved efficacy and fewer side effects, are shaping market dynamics. The shift towards personalized medicine is allowing for tailored treatments based on an individual’s genetic and metabolic profile, enhancing the effectiveness of therapies. The launch of novel drug classes like GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors has broadened the available treatment options, addressing the unmet needs of diabetic patients. Furthermore, the rise in combination therapies that target multiple mechanisms of diabetes control has proven to be beneficial in improving patient compliance and treatment outcomes, which is driving the demand for such drugs.

However, the market also faces several challenges. The high cost of newer diabetes medications, particularly biologics and insulin analogs, remains a significant barrier for patients, particularly in developing countries where affordability is a concern. The increasing focus on cost-effective treatment options and the availability of generic versions of diabetes drugs are expected to help mitigate these challenges. Additionally, the potential for adverse side effects and the complexity of diabetes treatment regimens are concerns that require ongoing research and development. Despite these challenges, opportunities abound in the development of next-generation diabetes drugs, which promise more effective and patient-friendly therapies, helping to drive market growth in the coming years.

Key Market Drivers

Rising Prevalence of Diabetes

The rising prevalence of diabetes is a key driver for the growth of the Global Diabetes Drugs Market. As the incidence of diabetes continues to increase globally, the demand for diabetes medications has surged. The global population is experiencing lifestyle changes, with factors such as poor diets, sedentary lifestyles, and increasing obesity contributing to a higher risk of developing Type 2 diabetes. The aging population is also a significant factor, as the risk of developing diabetes increases with age. More individuals are being diagnosed with diabetes, and this trend is especially pronounced in emerging markets, where urbanization and changing dietary patterns are accelerating the rise of the disease.

According to a study published in The Lancet in November 2024, the number of adults living with diabetes worldwide has surpassed 800 million, more than quadrupling since 1990. The analysis, conducted by the NCD Risk Factor Collaboration with support from the World Health Organization (WHO), highlights the scale of the diabetes epidemic and an urgent need for stronger global action to address both rising disease rates and widening treatment gaps, particularly in low- and middle-income countries.

The increase in diabetes prevalence is not only leading to a higher number of diagnosed patients but is also pushing healthcare systems to adapt and expand their diabetes care infrastructure. Many patients are now seeking ongoing treatment to manage the condition and prevent complications such as heart disease, stroke, kidney failure, and blindness. The growth in diagnosed cases is driving the demand for both insulin and non-insulin-based diabetes medications. Additionally, as diabetes is recognized as a major risk factor for cardiovascular disease, there is an increasing need for medications that address both glucose control and cardiovascular health.

As awareness about the disease grows and healthcare providers become more adept at diagnosing and managing diabetes, patients are becoming more engaged in their treatment, resulting in higher drug consumption. This growing patient base is fueling market demand and encouraging pharmaceutical companies to develop innovative drugs that offer better efficacy, fewer side effects, and more convenient administration. The rising prevalence of diabetes, combined with the expanding patient base and the need for long-term management, creates a strong market environment for diabetes drugs and drives sustained market growth.

Advancements in Drug Development and Drug Formulations

Advancements in drug development and drug formulations are significant drivers of the Global Diabetes Drugs Market, playing a crucial role in improving treatment outcomes and addressing the evolving needs of patients. The introduction of newer classes of drugs, such as GLP-1 receptor agonists (e.g., Liraglutide and Semaglutide) and SGLT2 inhibitors (e.g., Empagliflozin and Canagliflozin), has transformed diabetes management. These drugs not only target blood glucose levels more effectively but also provide additional benefits, such as weight loss, improved cardiovascular health, and kidney protection, which are essential for managing the multifaceted nature of diabetes. Unlike older medications, these newer formulations address the core pathophysiological mechanisms of diabetes, making them more efficient in controlling blood sugar levels while reducing the risk of associated complications.

Innovations in insulin formulations have also played a vital role in advancing diabetes care. The development of long-acting insulin analogs, such as insulin glargine and insulin degludec, has provided patients with more stable blood sugar control and reduced the frequency of injections. These insulin formulations offer extended duration of action, allowing for better management with fewer doses, contributing to improved patient adherence. Combination therapies, which combine two or more drugs with complementary mechanisms, are another breakthrough in the market. These formulations streamline treatment regimens, improving patient compliance and enhancing therapeutic outcomes by targeting multiple pathways in glucose regulation.

The continuous research and development in drug formulations, including the formulation of oral insulin and advanced drug delivery systems like smart insulin pens and insulin pumps, have led to more personalized and convenient treatment options. These advancements are driving demand for more effective and patient-friendly diabetes medications, pushing the market toward greater innovation and growth.

Government Support and Health Initiatives

Government support and health initiatives are pivotal in addressing the escalating global diabetes crisis. In 2022, the International Diabetes Federation (IDF) reported that India had the highest number of adults with diabetes, with over 212 million affected individuals. Alarmingly, nearly 62% of these individuals were not receiving any treatment, highlighting a significant gap in diabetes care.

In response to this pressing health challenge, the Indian government has implemented several strategic measures to enhance diabetes care and treatment accessibility. The National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), under the National Health Mission (NHM), focuses on strengthening healthcare infrastructure, developing human resources, and promoting health awareness. This program aims to facilitate early diagnosis, effective management, and appropriate referrals for treatment.

A significant component of this initiative is the provision of free essential medicines, including insulin, to economically disadvantaged populations. The Free Drugs Service Initiative under NHM offers financial support to states and union territories, ensuring that essential medications are available at no cost to those in need. Additionally, the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) scheme collaborates with state governments to make quality generic medicines, including insulin, available at affordable prices, thereby reducing the financial burden on patients.

The Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (PMJAY) further complements these efforts by providing health insurance coverage to over 10.74 crore families, facilitating access to inpatient care for diabetes patients. This comprehensive approach underscores the government's commitment to improving diabetes care and treatment accessibility, aiming to reduce the prevalence of untreated diabetes and enhance health outcomes for affected individuals.

Download Free Sample Report

Key Market Challenges

High Cost of Diabetes Medications

The high cost of diabetes medications presents a significant challenge for the Global Diabetes Drugs Market, impacting both patients and healthcare systems. Newer classes of diabetes medications, such as GLP-1 receptor agonists and SGLT2 inhibitors, offer improved efficacy and fewer side effects compared to traditional drugs like insulin and metformin. However, these innovative treatments often come with high price tags, making them less affordable for many patients, particularly those without adequate insurance coverage. The cost burden is especially significant for people living with diabetes in low- and middle-income countries, where access to essential medications may already be limited.

For patients with chronic conditions like diabetes, the need for long-term treatment compounds the financial burden. Many diabetes drugs require ongoing use, often for a lifetime, which can lead to high cumulative costs. As a result, patients may struggle to afford the necessary treatments, leading to poor medication adherence, suboptimal disease management, and an increased risk of complications. This can ultimately lead to higher overall healthcare costs due to hospitalizations, emergency treatments, and the management of comorbidities such as heart disease and kidney failure, which are common in diabetes patients.

Pharmaceutical companies, while investing heavily in research and development of innovative therapies, face pressure from governments, insurance providers, and consumers to make diabetes medications more affordable. The cost of producing biologic drugs, particularly for insulin, is also high due to the complex manufacturing processes involved. The market is also impacted by the rising cost of healthcare in developed countries, where prices for diabetes medications are escalating, making it increasingly difficult for both individuals and public healthcare systems to manage the financial burden of diabetes care.

Recent studies have highlighted the disparity in insulin pricing between high-income and low-income countries. In 2023, a survey revealed that a month's supply of insulin costs up to 27 days' salary in countries like Cameroon, Nigeria, and Myanmar, underscoring the affordability issue in poorer regions.

In the United States, the average annual cost per person with diabetes was approximately USD 12,000 in 2021, with prescription medications accounting for about 37% of total medical expenditures for individuals with diabetes. These statistics underscore the urgent need for strategies to reduce the cost of diabetes medications globally, ensuring that all patients have access to necessary treatments without financial hardship.

Complexity of Diabetes Management

The complexity of diabetes management is a significant challenge in the Global Diabetes Drugs Market. Diabetes is a chronic condition that requires continuous and multifaceted management, which includes monitoring blood glucose levels, adhering to medication schedules, and making lifestyle modifications. Patients often need to manage multiple medications, such as oral hypoglycemics, insulin, and newer drug classes like GLP-1 receptor agonists or SGLT2 inhibitors, depending on the severity of their condition. This creates a burden for patients who may struggle with complex regimens involving both oral and injectable therapies. The frequent need for insulin injections, glucose monitoring, and adherence to a specific diet and exercise routine adds to the daily demands of managing the disease.

The variety of available treatment options, while beneficial in providing individualized care, also adds complexity to the decision-making process for both healthcare providers and patients. Choosing the appropriate medication involves considering various factors such as the patient's age, comorbidities, response to previous treatments, and risk factors for complications. Patients often face difficulties in understanding their treatment plans and managing side effects, which can lead to non-compliance or suboptimal treatment outcomes.

Additionally, the constant need for healthcare monitoring, including regular check-ups, lab tests, and assessments, increases the strain on healthcare systems. This not only raises the overall cost of managing diabetes but also places pressure on healthcare professionals who must provide ongoing guidance and support. The combination of multiple medications, the potential for adverse side effects, and the challenges of managing the disease over the long term complicates the treatment landscape, making it difficult for patients to maintain consistent, effective diabetes control. This complexity is a key barrier to optimal disease management and limits the overall success of diabetes therapies.

Key Market Trends

Shift Toward Novel Drug Classes

A significant trend in the Global Diabetes Drugs Market is the shift toward novel drug classes, particularly GLP-1 receptor agonists and SGLT2 inhibitors, which are transforming diabetes management. These newer therapies offer more targeted and comprehensive treatment options compared to traditional medications like insulin and metformin. GLP-1 receptor agonists, such as semaglutide (marketed as Ozempic and Wegovy), mimic natural hormones to stimulate insulin production and slow gastric emptying, leading to improved blood glucose control and weight loss. SGLT2 inhibitors, like empagliflozin, work by preventing glucose reabsorption in the kidneys, thereby reducing blood sugar levels and offering additional benefits like cardiovascular protection.

The adoption of these novel drug classes has been accelerating. Between 2015 and 2020, the number of prescriptions for SGLT2 inhibitors in the United States doubled, and prescriptions for GLP-1 receptor agonists tripled during the same period.

This surge reflects a growing recognition of the efficacy and safety profiles of these medications. However, despite their benefits, the utilization rates of these drugs remain relatively low. As of 2020, only about 5.8% of adults with type 2 diabetes in the U.S. were using SGLT2 inhibitors, and 4.4% were using GLP-1 receptor agonists. This indicates a significant opportunity for increased adoption and integration into clinical practice.

The shift toward these novel therapies is driven by their ability to address multiple aspects of diabetes pathophysiology, including insulin resistance, pancreatic function, and cardiovascular health. Their introduction has led to improved patient outcomes, including better glycemic control, weight loss, and reduced cardiovascular risks. As healthcare providers become more familiar with these agents and as access improves, their use is expected to increase, further transforming the diabetes treatment landscape.

Emergence of Biosimilars and Generic Diabetes Drugs

The emergence of biosimilars and generic diabetes drugs is one of the most transformative trends in the Global Diabetes Drugs Market. As patents for several blockbuster diabetes medications, including insulin and GLP-1 receptor agonists, begin to expire, the market is witnessing an influx of generic versions and biosimilars, which are more affordable alternatives to branded drugs. These drugs are gaining popularity due to their lower cost, making them accessible to a larger population, especially in low-income and developing regions where access to expensive branded medications is limited. The entry of biosimilars, which are biologically similar to original insulin and other biologic drugs, has particularly impacted the market by driving down prices and creating more competition among pharmaceutical companies. This trend is beneficial for healthcare systems facing budget constraints, as biosimilars and generics provide an opportunity to manage the rising costs of diabetes treatment without compromising on the quality of care.

The increasing availability of generic drugs has created a shift in treatment options, especially for Type 2 diabetes, where oral medications such as metformin and glimepiride have become widely available in generic forms. These medications are prescribed at a lower cost compared to branded counterparts, improving patient access and adherence to treatment regimens. The trend also extends to insulin, with generics entering the market and offering more affordable options for patients who require lifelong insulin therapy. While the lower cost of these drugs helps to expand market access, it also intensifies competition among drug manufacturers, driving innovation and encouraging further research into new, more effective therapies. The emergence of biosimilars and generics represents a significant shift in the market, offering both economic and clinical benefits by enhancing treatment accessibility and reducing financial barriers for diabetes management.

Segmental Insights

Diabetes Type Insights

Based on the Diabetes Type, Type 2 Diabetes emerged as the dominant segment in the Global Diabetes Drugs Market in 2024. This is due to its higher prevalence compared to Type 1 diabetes and its association with lifestyle factors such as obesity, poor diet, and lack of physical activity. Type 2 diabetes accounts for approximately 90-95% of all diabetes cases globally, which significantly drives the demand for medications. As the global population ages and the incidence of obesity continues to rise, Type 2 diabetes has become a major health concern, contributing to the growing demand for effective treatment options. Additionally, the wide range of treatment options available for Type 2 diabetes, including oral medications, insulin therapies, and injectable drugs such as GLP-1 receptor agonists and SGLT2 inhibitors, further supports the market dominance of this segment. These newer medications not only improve glycemic control but also offer additional benefits, such as weight loss and cardiovascular protection, which makes them more attractive to patients. As awareness of the disease increases and healthcare systems improve their ability to diagnose and treat Type 2 diabetes, the demand for diabetes drugs continues to expand, further solidifying Type 2 diabetes as the largest and fastest-growing segment in the market.

Distribution Channel Insights

Based on the Distribution Channel, Retail Pharmacies emerged as the dominant segment in the Global Diabetes Drugs Market in 2024. This is due to their widespread accessibility, convenience, and established infrastructure. Retail pharmacies are easily reachable to most consumers, providing both prescription and over-the-counter diabetes medications, making them the go-to choice for many patients. With a vast network of physical stores, patients can quickly obtain their medications without waiting for delivery, which is especially crucial for those managing chronic conditions like diabetes that require regular and timely access to treatment. Additionally, retail pharmacies play a critical role in patient education and support. Many retail pharmacies offer counseling services, blood glucose monitoring, and diabetes management advice, which encourages patient compliance and engagement in their treatment regimen. The presence of pharmacy chains, independent stores, and the availability of multiple brands also contribute to the segment’s dominance, as patients have various options at competitive prices. With increasing awareness of diabetes and the need for continuous treatment, retail pharmacies have solidified their position as the primary distribution channel for diabetes drugs. This trend is further supported by healthcare reforms that ensure accessibility and affordability of diabetes treatments, making retail pharmacies an integral part of the diabetes care continuum.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the Global Diabetes Drugs Market in 2024. This is due to the high prevalence of diabetes, strong healthcare infrastructure, and substantial spending on healthcare. The United States, in particular, has a large diabetic population, with Type 2 diabetes being a major health concern driven by factors such as obesity, sedentary lifestyles, and an aging population. With over 30 million people living with diabetes in the U.S. alone, the demand for diabetes drugs is consistently high. Additionally, North America benefits from advanced healthcare systems, including wide access to healthcare services and diabetes treatments, which makes it easier for patients to receive timely diagnosis and treatment. The region also sees a significant investment in research and development, leading to the introduction of innovative therapies such as GLP-1 receptor agonists and SGLT2 inhibitors. Furthermore, healthcare providers in North America are proactive in educating patients about managing diabetes, leading to higher medication adherence rates. Insurance coverage, government healthcare programs, and private sector investments also play a key role in facilitating access to medications. As a result of these factors, North America continues to lead in terms of revenue generation and market share within the global diabetes drugs market.

Recent Developments

• In August 2024, Eli Lilly & Co. announced positive topline results from the three-year SURMOUNT-1 study, demonstrating that weekly tirzepatide injections (5 mg, 10 mg, 15 mg) reduced the risk of developing Type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight. The study found that tirzepatide, marketed as Zepbound and Mounjaro, also led to significant weight loss, with adults on the 15 mg dose experiencing an average 22.9% reduction in body weight, compared to 2.1% in the placebo group. The treatment showed long-term efficacy in weight management and delaying diabetes progression.
• In April 2024, Sanofi India Limited launched its new diabetes drug, Soliqua, following marketing authorization from the Central Drugs Standard Control Organisation (CDSCO) in 2023. Soliqua is indicated for the treatment of adults with obesity and Type 2 diabetes mellitus, aimed at improving glycemic control in patients inadequately managed by oral or injectable therapies, alongside diet and exercise.
• In January 2024, Glenmark Pharmaceuticals Ltd. launched its biosimilar of the popular anti-diabetic drug Liraglutide in India. Marketed as Lirafit, the drug received approval from the Drug Controller General of India (DCGI). Priced at INR 100 for a 1.2 mg daily dose, it offers a 70% reduction in therapy costs and will be available only by prescription.
• In June 2023, Pfizer Inc. announced its decision to advance the clinical development of danuglipron (PF-06882961), an oral GLP-1 receptor agonist, for the potential treatment of obesity and Type 2 diabetes mellitus (T2DM), pending results from the ongoing Phase 2 trial. Pfizer plans to finalize the late-stage program for danuglipron by the end of 2023 and is working on a once-daily modified release version.
• In February 2023, Akums Drugs and Pharmaceutical Limited, a contract drug manufacturing company, announced the launch of Lobeglitazone, a new drug for the treatment of Type 2 diabetes.

Key Market Players

• Novo Nordisk A/S
• Sanofi
• Merck & Co., Inc.
• Eli Lilly and Company
• AstraZeneca PLC
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH
• Novartis AG
• Bayer AG
• Pfizer Inc.

Report Scope:

In this report, the Global Diabetes Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Diabetes Drugs Market, By Drug Class:

o   Insulin

o   DPP-4 Inhibitors

o   GLP-1 Receptor Agonists

o   SGLT2 Inhibitors

o   Others

• Diabetes Drugs Market, By Diabetes Type:

o   Type 1

o   Type 2

o   Gestational

• Diabetes Drugs Market, By Route of Administration:

o   Oral

o   Subcutaneous

o   Intravenous

• Diabetes Drugs Market, By Distribution Channel:

o   Online Pharmacies

o   Hospital Pharmacies

o   Retail Pharmacies

o   Others

• Diabetes Drugs Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetes Drugs Market.

Available Customizations:

Global Diabetes Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Diabetes Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]